>  
Report Detail

Global Markets for Asthma and COPD Drugs

Publisher Name :
Date: 14-Aug-2012
No. of pages: 136

REPORT HIGHLIGHTS

  • The global market for asthma and chronic obstructive pulmonary disease (COPD)  prescription drugs was valued at $34.9 billion in 2011. This figure is projected to reach $38 billion in 2012 and $47.1 billion in 2017, increasing at a five-year compound annual growth rate (CAGR) of 4.4%.
  • Combination asthma/COPD drugs are expected to be worth $17.4 billion in 2012 and should reach $21.3 billion in 2017, a CAGR of 4.1%.
  • The segment made up of asthma drugs is projected to increase from $15.3 billion in 2012 to $20.2 billion in 2017, a CAGR of 5.7%.
  • COPD drugs are expected to increase from $5.3 billion in 2012 to $5.6 billion in 2017, a CAGR of 1.2%.

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This study is intended to provide readers with an understanding of the global market for asthma and chronic obstructive pulmonary disease (COPD) prescription drugs. The study outlines the industry structure, competitive aspects, current developments, and future trends in the market, to assist in identifying areas of commercial interest and potential in the asthma and COPD indications.

The objectives of the study include the assessment of current market status, the analysis of marketed drugs, market revenues, company shares, unmet market needs, market challenges, and future trends. Future market revenues are forecast for the global market, major drug classes, individual disease indication, and largest geographical regions. The study also reviews the compounds currently being investigated in clinical studies for the treatment of asthma and COPD.

REASONS FOR DOING THE STUDY

Asthma and COPD are two diseases experiencing increasing prevalence globally due to a combination of factors, including a globally aging population and increasing pollution levels. COPD is one of the top five causes of disability and death in industrialized countries and the fourth-leading cause of death globally.

The market for asthma and COPD drugs had global revenues in 2010 that exceeded $34 billion annually. These drugs enjoy tremendous commercial success, as illustrated by the presence of six currently marketed multibillion-dollar drugs in this market. However, there is a perceived high level of unmet need in this market in terms of treatment options for asthma and COPD patients.

With the loss of patent protection on several major COPD and asthma drugs between 2010 and 2017, the cost for some treatments is expected to decrease as generic versions gain market share. Additionally, several new drugs are projected to enter the market through 2017, and they will continue to drive growth of revenues for asthma and COPD drugs.

SCOPE OF REPORT

The report provides a current market overview and projects future developments in the asthma and COPD drugs market over the period from 2011 through 2017. The report describes existing drug classes approved for these indications, such as bronchodilators, anti-inflammatory drugs, and combination drugs of inhaled corticosteroids and bronchodilators. The pipeline of drugs in clinical trials for these indications is also presented and analyzed.

The report includes the following major sections:

  • Disease overview.
  • Industry structure and competitive analysis including tiers of competition; regulatory aspects; competitive factors; and market needs, challenges, and trends
  • Overall market revenue forecast and current market shares as well as revenue forecast by major drug classes, disease indication, and geographical regions.
  • In-depth analyses of current drug classes.
  • Reviews and analyses of compounds in clinical trials, with an emphasis on drugs in advanced stages of development.

The report will also analyze product sales and demographics in three regional markets: The Americas (U.S., Canada, Latin/South America); Europe, Middle East, Russia, Africa (EMRA); and Asia (Japan, Australia/New Zealand, other Asian nations, including India and China).

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. The analyses and data presented in this report are based on information collected from a variety of industry sources, including pharmaceutical manufacturers and end users. Secondary information sources include company financials and documentation, U.S. Securities and Exchange Commission (SEC) filings, the U.S. Patent and Trademark Office (USPTO), MEDCO Health, World Health Organization (WHO), trade organizations and their publications, online databases, and the medical and scientific literature.

The base year for analysis and forecast is 2011. Revenue forecasts are provided for the period 2012 to 2017. The forecasts are based on a comprehensive analysis of a variety of market and product-specific factors, including historical, current, and future trends; existing and undiagnosed patient populations; unmet market needs; existing product patent expiration dates; the impact of the generic market; and new market entrants and their value proposition and differentiation.

Values are given in U.S. dollars, forecasts are made in constant U.S. dollars, and growth rates are compounded. Currency conversions were made in June 2012. Growth rates were calculated based on existing and proposed device and equipment sales, at manufacturer pricing, during the forecast period.

INTENDED AUDIENCE

This report provides information that is useful for business planners, market researchers, marketers, business developers, investors, venture capitalists, consultants, and anyone who wants to understand or invest in this market. The information is also useful for technology licensing and scientific research and development purposes.

INFORMATION SOURCES

The analysis and data presented in this report are based on information collected from a variety of industry sources, including the pharmaceutical manufacturers that currently market prescription drugs in this therapeutic area and research- based companies that develop new drug candidates for these indications, as well as end users of prescription drugs. Secondary information sources include company websites, financials, and other literature; SEC filings; patents issued by the USPTO; trade organizations and publications; online databases; and medical and scientific literature.

ANALYST CREDENTIALS

Peggy S. Lehr is the BCC Research analyst of this report. Ms. Lehr holds a BS in Journalism from the University of Colorado, Boulder, and an MS in Communication from the University of Denver. Ms. Lehr has worked within the publishing industry for both for-profit and not-for-profit organizations, and she has completed more than 20 reports for BCC.

Global Markets for Asthma and COPD Drugs

Chapter- 1: Introduction
Study Goals And Objectives
Reasons For Doing The Study
Scope Of Report
Methodology
Intended Audience
Information Sources
Analyst Credentials
Related Bcc Reports
Bcc Online Services
Disclaimer

Chapter- 2: Summary
Table Summary : Global Market For Asthma And Copd Prescription Drugs By Disease, Through 2017
Figure Summary : Global Market For Asthma And Copd Prescription Drugs By Region, 2012 And 2017

Chapter- 3: Overview
Pulmonary Drug Delivery
Pulmonary Conditions And Therapies
Respiratory System
Drug Development Process
Industry Players
Acquisitions And Mergers
Competitive Factors
Significant Trends
Market Challenges
Filling Unmet Needs
Regional Analysis

Chapter- 4: Disease Overview
Symptom Comparisons
Asthma Overview
Chronic Obstructive Pulmonary Disease
Regional Statistics

Chapter- 5: Markets By Drug Class
Bronchodilators
Biological Drugs
Combination Ics/Laba Drugs
Table 14 : Projected Global Market For Asthma And Copd Drug, By Drug Class, Through 2017

Chapter- 6: Markets By Disease
Asthma Drugs
Chronic Obstructive Pulmonary Disease
Figure 11 : Global Market For Asthma And Copd Prescription Drugs By Disease, 2011

Chapter- 7: Emerging Trends And Product Pipeline Review
The "Asthma Gene"
Oral Drugs For Asthma
Disease Modifying Drugs
Asthma Formulations
Copd Formulations
Novel Biologics
Ultra Long-Acting Muscarinic Antagonists
Ultra Long-Acting B2 Agonists (Ultra-Laba)
Lama And Laba Combination Drugs
Anti-Inflammatory Drugs
Anti-Protease
Chemokine Antagonists
Ppar Agonists
Asthma/Copd Drug Development, By Company
Asthma Devices

Chapter- 8: Approved Drugs And Patent Review
Patent Review
Table 43 : Approved Drugs To Treat Asthma And Copd, 1996 Through 2011
Table 44 : Drugs Seeking Approval To Treat Asthma And Copd 2012 Through 2013

Chapter- 9: Company Profiles
Actient Pharmaceuticals
Aerovance, Inc.
Almirall, S.A.
Amgen Inc.
Aptar Pharma
Argenta Discovery, Ltd.
Astrazeneca
Boehringer Ingelheim Gmbh
Chiesi Farmaceutici Spa
Cornerstone Therapeutics
Cytos Biotechnology Ag
Dey Pharma (Mylan Specialty L.P.)
Forest Laboratories, Inc.
Genentech, Inc. (Roche)
Glaxo Wellcome U.K., Ltd.
Medicinova
Medicis Pharmaceutical
Medimmune
Merck & Co., Inc.
Novartis Pharma
Nycomed International (Takeda International)
Osiris Therapeutics, Inc.
Pfizer, Inc.
Sepracor, Inc. (Sunovion)
Skyepharma Plc
Teva Pharmaceutical Industries, Ltd.
Theravance
Topigen Pharmaceuticals, Inc. (Pharmaxis Ltd)
Vectura Group Plc

List Of Tables

Summary Table : Global Market For Asthma And Copd Prescription Drugs By Disease, Through 2017
Table 1 : Marketed Asthma And Copd Drug Classes
Table 2 : Net Revenues For Top Six Asthma/Copd Product Manufacturers, With Product(S), 2010 And 2011
Table 3 : Net Revenues For Top Specialty Asthma/Copd Manufacturers With Product(S), 2010 And 2011
Table 4 : Net Revenues For Smaller Asthma/Copd Product Manufacturer, With Product, 2010 And 2011
Table 5 : Acquisitions And Mergers In The Asthma And Copd Market, January 2008 To June 2012
Table 6 : Major Asthma/Copd Drugs That Lose Patent Protection Between 2008 And 2024
Table 7 : Asthma And Copd Symptom Comparisons
Table 8 : Classification Of Asthma, By Symptoms
Table 9 : Asthma And Copd Drug Classes
Table 10 : Classification Of Copd And Asthma
Table 11 : Percent Of Selected Populations With Diagnosed Asthma In The Americas
Table 12 : Percent Of Selected Populations With Diagnosed Asthma In The Emra
Table 13 : Percent Of Selected Populations With Diagnosed Asthma In Asia
Table 14 : Projected Global Market For Asthma And Copd Drug, By Drug Class, Through 2017
Table 15 : Projected Global Market For Bronchodilators, Through 2017
Table 16 : Short-Acting Beta-2 Agonists, With Approval And Patent Expiry Dates, 2011
Table 17 : Projected Market For Short-Acting Beta-2 Agonist Bronchodilators, Through 2017
Table 18 : Long-Acting Beta-2 Agonists, 2011
Table 19 : Projected Global Market For Laba Products, Through 2017
Table 20 : Anticholinergics And Combination Anticholinergics/Saba By Manufacturer, 2011
Table 21 : Projected Global Market For Anticholinergics, Through 2017
Table 22 : Projected Global Market For Anti-Inflammatory Drugs By Type, Through 2017
Table 23 : Inhaled Corticosteriods, 2011
Table 24 : Projected Global Market For Inhaled Corticosteroids, Through 2017
Table 25 : Leukotriene Modifiers, 2011
Table 26 : Projected Global Market For Leukotriene Modifiers, Through 2017
Table 27 : Projected Global Market For Pde-4 Drugs, Through 2017
Table 28 : Projected Global Market For Asthma Biological Drugs, Through 2017
Table 29 : Combination Ics/Laba Drugs, 2011
Table 30 : Projected Global Market For Combination Ics/Laba Drugs, Through 2017
Table 31 : Projected Revenues From Asthma/Copd Drugs By Region, Through 2017
Table 32 : Projected Revenues From Asthma/Copd Drugs In The Americas Region, Through 2017
Table 33 : Projected Use Of Asthma/Copd Drugs In The Americas' Region, Through 2017
Table 34 : Projected Revenues From Asthma/Copd Drugs In The Emra, Through 2017
Table 35 : Projected Use Of Asthma/Copd Drugs In The Emra Region, Through 2017
Table 36 : Projected Revenues From Asthma/Copd Drugs In The Asian Region, Through 2017
Table 37 : Projected Use Of Asthma/Copd Drugs, By Region In Asia, Through 2017
Table 38 : Projected Global Market For Asthma Prescription Drugs, Through 2017
Table 39 : Projected Global Market For Copd Prescription Drugs, Through 2017
Table 40 : Projected Global Market For Combination Asthma/Copd Drugs, Through 2017
Table 41 : Projected Global Market For Combination Asthma/Copd Prescription Drugs, Through 2017
Table 42 : Asthma/Copd Products Under Development, By Company, 2012
Table 43 : Approved Drugs To Treat Asthma And Copd, 1996 Through 2011
Table 44 : Drugs Seeking Approval To Treat Asthma And Copd 2012 Through 2013
Table 45 : Asthma/Copd Treatment Patents, By Company, Disease, Patent Number, Year Filed, 2011 Through 2012
Table 46 : Asthma/Copd Treatment Patents, By Number, Company, Description, And Date Issued, 2011 Through 2012
Table 47 : Asthma/Copd Drug Treatment Patents Issued Between January 2011 And May 2012, By Company

List Of Figures

Summary Figure : Global Market For Asthma And Copd Prescription Drugs By Region, 2012 And 2017
Figure 1 : Global Bronchodilator Market, By Type, 2012 And 2017
Figure 2 : Global Market Share For Bronchodilators By Company, 2011
Figure 3 : Market Share For Laba Bronchodilators By Company, 2011
Figure 4 : Market Share Of Anti-Inflammatory Drugs By Type, 2012 And 2017
Figure 5 : Market Share Of Leading Manufacturers Of Inhaled Corticosteriods, 2011
Figure 6 : Global Market For Leukotriene Modifiers, By Manufacturer, 2012 And 2017
Figure 7 : Market Share Of Manufacturers Of Ics/Laba, 2011
Figure 8 : Market Percent Of Asthma/Copd Drugs In The Americas Region, 2012 And 2017
Figure 9 : Market Percent Of Asthma/Copd Drugs In The Emra, 2012 And 2017
Figure 10 : Market Percentage Of Asthma/Copd Drugs, By Region In Asia, 2012 And 2017
Figure 11 : Global Market For Asthma And Copd Prescription Drugs By Disease, 2011
Figure 12 : Market Shares Of Leading Manufacturers Of Asthma Drugs, 2011
Figure 13 : Market Shares Of Leading Manufacturers Of Copd Drugs, 2011
Figure 14 : Market Shares Of Leading Manufacturers Of Combination Asthma/Copd Drugs, 2011
Figure 15 : Percent Of Reviewed Patents For Asthma, Copd, And Combination Use, January 2011 To May 2012
Figure 16 : Asthma/Copd Patents, By Country, 2011 Through 2012

  • Importance of Optical Material in Day-to-Day Life
    The most common form of optical material is in telecommunications and instruments that measure intensity, polarization and wavelength of various substances. Optical fibers are light, thin, transparent and flexible materials that act as a strong waveguide. These are a sort of glass or plastic conduits that are used for transporting light. Although invented long ago, [...]
  • Most Effective Drugs for the Treatment of Multiple Sclerosis
    Also known as disseminated sclerosis, multiple sclerosis (MS) is a severe inflammatory disease. In this disease, the myelin sheath around the axon tissues of the spinal cord and brain are damaged. The loss of myelin or demyelination leads to the loss of abilities of the nerve cells. this loss is irreversible, which affects the communication [...]
  • Three Tips to Choose the Best Business Web Hosting Service
    Most businesses are choosing web-based services for the convenience and additional features that they offer. Web hosting is a common internet service, which is preferred by the businesses to launch their businesses online. It is a simple process of renting a space on the server, which allows data storage. This space and data can be [...]
  • Antimalarials- Common Malaria Drugs for Fast Recovery
    Malaria is one of the better-known types of the mosquito-borne infectious disease. This disease is caused by microorganisms known as protists, which are introduced into the human body thorough the bites of an infected female mosquito. Along with the common flu-like symptoms, malaria also causes several other health conditions such as gastroenteritis, septicemia and viral [...]
  • How to Choose the Best Multicasting Router
    Communication is the basic of computer networking. Multicasting is a common communication process in computing, which takes place in the computing environment. Multicast is the delivery of information to a group of computers through single transmission. Digital copies of this transmission are automatically created in various other network elements. In simple terms, it is similar [...]
  • Travel and Tourism in Portugal to 2017

    • After declining in 2009 due to the global financial crisis, the rate of inbound tourism within the Portuguese travel and tourism sector improved. The country recorded an increase in the number of international visitors and tourist expenditure, primarily due to …

  • Construction in Western Europe – Key Trends and Opportunities to 2017

    • Western Europe experienced a severe financial crisis during 2008 – 2009, with economic activity in the region contracting sharply. Reflecting ongoing weakness in the region, real GDP has yet to rise above the pre-2008 level, with ongoing debt problems in …

  • The Insurance Industry in Turkmenistan, Key Trends and Opportunities to 2017

    • The Turkmen insurance industry is very small, both in terms of size and significance. Insurance penetration stood at just 0.2% in 2012, compared to the global average of 6.7%. Between 2008 and 2012 the industry achieved significant written premium value …

  • Construction in Thailand – Key Trends and Opportunities to 2017

    • The Thai construction industry suffered a double blow between 2008 and 2012, firstly from the global economic crisis in 2008 -2009 and then from the record breaking floods in 2011, with activity levels declining by 5.3% in 2008 and 2.35 …

  • Construction in Tunisia – Key Trends and Opportunities to 2017

    • Between 2008 and 2012 the Tunisian construction industry grew at a CAGR of 5.58% and valued TND8.9 billion (US$5.7 billion) in 2012. This was supported by private and public investments in infrastructural, residential, industrial and commercial construction projects. Despite some …

  • Market and Product Forecasts: Asthma – Premium products to offset loss to generics
    "...... positive growth such that the market will maintain value, with a CAGR over 2012–21 of 0.1%. Features and benefits Access Datamonitor’s patient-based asthma market forecast for the seven major markets, with transparent methodology and clear ass......"
  • Market and Product Forecasts: Asthma in China – Market set to fragment as novel therapies launch
    "......eceiving asthma treatment, considerable untapped patient potential will remain. Features and benefits Access Datamonitor’s patient-based asthma market forecast for Chinese Tier 1 and Tier cities, with transparent methodology and clear assump......"
  • Epidemiology: Asthma – Stable prevalence rates in all age groups will lead to stable case numbers
    "...... during this period. Features and benefits Gain insight into market potential, including robust 10-year epidemiology forecasts of active diagnosed prevalent asthma cases. Gain insight into relevant clinical severity of active diagnosed asthma cases i......"
  • Epidemiology: Asthma in China – Aging population and rising urbanization increase asthma prevalence
    "......creasing urbanization. Features and benefits Gain insight into market potential, including a robust 10-year epidemiology forecast of prevalent asthma cases. Understand the key epidemiologic risk factors associated with asthma. Highlights Dat......"